- 1 Estimating the contribution of HIV-infected adults to household pneumococcal transmission in
- 2 South Africa, 2016-2018: A hidden Markov modelling study.
- 4 Authors

- 5 Deus Thindwa^{1,2*}, Nicole Wolter^{3,4}, Amy Pinsent^{1,5}, Maimuna Carrim³, John Ojal^{1,6}, Stefano
- 6 Tempia^{3,7,8,9}, Jocelyn Moyes³, Meredith McMorrow⁸, Jackie Kleynhans^{3,10}, Anne von Gottberg^{3,4}, Neil
- 7 French^{2,11}, Cheryl Cohen^{3,10‡}, Stefan Flasche^{1‡} on behalf of PHIRST group[†]
- 8
 9 ¹Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease
- 10 Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
- ² Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
- 12 ³ Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of
- the National Health Laboratory Service, Johannesburg, South Africa.
- ⁴ School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
- 15 ⁵ Aquarius Population Health, London, UK.
- 16 ⁶ KEMRI-Wellcome Trust Research Programme, Geographic Medicine Centre, Kilifi, Kenya.
- ⁷ Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.
- 18 Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- 19 ⁹ MassGenics, Duluth, Georgia, USA.
- 20 ¹⁰ School of Public Health, Faculty of Health Science, University of the Witwatersrand, Johannesburg,
- 21 South Africa.

24

27

- 22 ¹¹ Institute of Infection, Veterinary and Ecological Science, Department of Clinical Infection,
- 23 Microbiology, and Immunology, University of Liverpool, Liverpool, UK.
- 25 ‡ These authors contributed equally
- † Membership of the PHIRST group is provided in the Acknowledgements.
- 28 * Corresponding author
- 29 Email: deus.thindwa@gmail.com
 - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Human immunodeficiency virus (HIV) infected adults are at a higher risk of pneumococcal colonisation and disease, even while receiving antiretroviral therapy (ART). To help evaluate potential indirect effects of vaccination of HIV-infected adults, we assessed whether HIV-infected adults disproportionately contribute to household transmission of pneumococci. We constructed a hidden Markov model to capture the dynamics of pneumococcal carriage acquisition and clearance observed during a longitudinal household-based nasopharyngeal swabbing study, while accounting for sample misclassifications. Households were followed-up twice weekly for 10 months for nasopharyngeal carriage detection via real-time PCR. We estimated the effect of participant's age, HIV status, presence of a HIV-infected adult within the household and other covariates on pneumococcal acquisition and clearance probabilities. Of 1,684 individuals enrolled, 279 (16.6%) were younger children (<5 years-old) of whom 4 (1.5%) were HIV-infected and 726 (43.1%) were adults (≥18 years-old) of whom 214 (30.4%) were HIV-infected, most (173, 81.2%) with high CD4+ count. The observed range of pneumococcal carriage prevalence across visits was substantially higher in younger children (56.9-80.5%) than older children (5-17 years-old) (31.7-50.0%) or adults (11.5-23.5%). We estimate that 14.4% (95% Confidence Interval [CI]: 13.7-15.0) of pneumococcalnegative swabs were false negatives. Daily carriage acquisition probabilities among HIV-uninfected younger children were similar in households with and without HIV-infected adults (hazard ratio: 0.95, 95%CI: 0.91-1.01). Longer average carriage duration (11.4 days, 95%CI: 10.2-12.8 vs 6.0 days, 95%CI: 5.6 - 6.3) and higher median carriage density (622 genome equivalents per millilitre, 95%CI: 507-714 vs 389, 95%CI: 311.1-435.5) were estimated in HIV-infected vs HIV-uninfected adults. The use of ART and antibiotics substantially reduced carriage duration in all age groups, and acquisition rates increased with household size. Although South African HIV-infected adults on ART have longer carriage duration and density than their HIV-uninfected counterparts, they show similar patterns of pneumococcal acquisition and onward transmission.

Author summary

We assessed the contribution of HIV-infected adults to household pneumococcal transmission by applying a hidden Markov model to pneumococcal cohort data comprising 115,595 nasopharyngeal samples from 1,684 individuals in rural and urban settings in South Africa. We estimated 14.4% of sample misclassifications (false negatives), representing 85.6% sensitivity of a test that was used to detect pneumococcus. Pneumococcal carriage prevalence and acquisition rates, and average duration were usually higher in younger or older children than adults. The use of ART and antibiotics reduced the average carriage duration across all age and HIV groups, and carriage acquisition risks increased in larger household sizes. Despite the longer average carriage duration and higher median carriage density in HIV-infected than HIV-uninfected adults, we found similar carriage acquisition and onward transmission risks in the dual groups. These findings suggest that vaccinating HIV-infected adults on ART with PCV would reduce their risk for pneumococcal disease but may add little to the indirect protection against carriage of the rest of the population.

Introduction

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

Streptococcus pneumoniae (pneumococcus) caused an estimated 3.7 million cases of invasive pneumococcal disease (IPD) and 317,300 deaths in children <5 years-old, globally in 2015 [1,2]. While severe disease is largely concentrated in young children and older adults, human immunodeficiency virus (HIV)-infected adults are also at an increased risk of both colonisation and IPD [3-7]. HIV affects the T and B cell function, resulting in impaired responses to control pneumococcal carriage at mucosal level [8–10]. Although the universal scale-up of antiretroviral therapy (ART) [11,12] has successfully reduced IPD risk in HIV-infected adults [13,14], the IPD risk remains elevated if compared to HIV-uninfected adults [5,6]. ART partially reconstitutes mucosal immunity by increasing B and T cell quantity and functionality [8,15], but deficiencies in humoral mucosal response due to depleted or persistent defects in memory cell function persist after ART initiation [16–18]. Despite mature pneumococcal conjugate vaccine (PCV) infant immunisation programmes, continued circulation of vaccine preventable serotypes in adults has been observed throughout Africa [19–25]. In some countries, such as Malawi, Mozambique, and Kenya, this intersects with areas of high HIV prevalence. Adult HIV prevalence in Africa remains high [26] as a consequence of improved survival with ART use [11,12] and persistently high HIV incidence [27], thus the high risk of pneumococcal carriage and IPD in HIV-infected adults in Africa remains a concern. Vaccination of African HIV-infected adults with PCV, similar to the recommendations in many highincome countries, may not only reduce their disease burden but also vaccine serotype pneumococcal acquisition and hence onward transmission and may thus benefit non-vaccinated populations [28]. We hypothesised that children living with HIV-infected adults have higher rates of pneumococcal carriage acquisition due to increased exposure from frequently colonised HIV-infected adults who usually have a prolonged higher carriage prevalence [5]. In this study, we assessed whether HIV-infected

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

adults contribute more to pneumococcal transmission within the household than their HIV-uninfected counterparts. Methods **Data description** The temporal dynamics of pneumococcal colonisation were observed in a cohort study (Prospective Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community Burden and Transmission Dynamics - PHIRST) conducted between 2016 and 2018 in a rural (Agincourt) and an urban (Klerksdorp) community in South Africa. Households were randomly selected, and were eligible for the study if they had ≥3 household members and the household members resided in the household for ≥1 year prior to study commencement, had no plan to relocate during study duration, and consented to participate in the study. Also, enrolment ensured that more than half of the households included at least one child aged <5 years, and a new cohort was enrolled every study year [29,30]. A total of 1,684 individuals from 327 households were enrolled and followed up from May to October in 2016 and January to October in 2017 and 2018. The median household size was 5 (interquartile range 4-7). Nasopharyngeal (NP) swabs were taken twice weekly, resulting in 115,595 total NP samples from 1,684 individuals [28]. The swabs were tested for the presence of pneumococci using real-time quantitative polymerase chain reaction (qPCR), targeting the autolysin (lytA) gene [31]. Serotyping was not performed. On enrolment, all household members were tested for HIV infection and the demographic characteristics of the study participants was recorded. **Modelling framework** We used a continuous time, time homogeneous, hidden Markov model (HMM) which assumed a Susceptible – Infected – Susceptible (SIS) framework [32–38], to fit to individual level trajectories of colonisation during the study period. An individual can be either infected (I) and currently carrying

124 pneumococci or be susceptible (S). Thus, the model can be described by transition intensities between 125 S and I for acquisition (q_{12}) and clearance (q_{21}) in the transition intensity matrix Q = $\begin{pmatrix} -q_{12} & q_{12} \\ q_{21} & -q_{21} \end{pmatrix}$. Covariates for acquisition and clearance rates are incorporated via a proportional 126 hazard. To obtain the transition probabilities, matrix $P = \begin{pmatrix} 1 - p_{12} & p_{12} \\ p_{21} & 1 - p_{21} \end{pmatrix}$ is defined and 127 explicitly calculated through matrix exponential, $P = \exp(Q(t))$, where p_{12} is the probability of 128 129 being in state 2 (I) at time t > 0, given that the previous state was 1 (S). A more detailed description 130 of the Markov transition process is provided in the Supplement. 131 132 In the hidden Markov modelling (HMM) framework [34,39–44], the states S and I of the Markov 133 Chain $(X_i(t))$ for individual i at time t are not observed directly, but approximated by the results of a 134 NP swab. The link between the modelled, true infection status and observed pneumococcal carriage 135 states in the model $(Y_i(t))$ is governed by emission probabilities conditional on the unobserved state. 136 We assumed 100% specificity of the NP swab and the PCR (no false positive) while estimating the 137 proportion of false negative results (e) probabilistically (observed vs hidden/truth states). Hence, the emission matrix is given as $E = \begin{pmatrix} 1 & 0 \\ e_{21} & 1 - e_{21} \end{pmatrix}$ where $e_{21} = \Pr(Y_i(t) = 1 \mid X_i(t) = 2)$. 138 139 140 We assumed that the observed states are conditionally independent given the values of the unobserved 141 states and that the future Markov chain is independent of its history beyond the current state (Markov 142 property) (Fig 1). Thus, the likelihood is the product of the emission probability density and the 143 transition probability of hidden Markov chain summed over all possible paths of the hidden states 144 (explicitly defined in the Supplement). 145 146 Our model assumed that carriage acquisition at the current observation point was a function of 147 individual age group (younger child aged <5 years, older child aged 5-17 years, or adult aged ≥18 148 years), HIV status (infected or uninfected), number of HIV-infected adult(s) in the household, place 149 of carriage exposure (household or community), and household size. Carriage duration was modified

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

by individual age, HIV status, ART status, and antibiotic use. The place of carriage exposure is generally unknown without fine-scale serotype data. Crudely, we assumed that if a household member is currently infected while all other household members were susceptible at the last observation point, then current carriage acquisition of that member was attributable to community transmission [34]. Otherwise we assumed that the transmission was from within the same household (Fig 1). Model fit, convergence and prediction The model was fitted to longitudinal data of pneumococcal carriage dynamics in a maximum likelihood framework using Bound Optimisation By Quadratic Approximation optim algorithm facilitated by msm R package [34,45]. To ascertain convergence of the model, we purposefully selected five unique pairs of initial transition intensities {S, I} for the Q matrix, then refitted the model five times, each time starting a Markov chain with a unique dyad and iterating 1,000 times to obtain similar final transition intensities and -2log-likelihood. Model predictions were assessed by comparing infection and susceptibility prevalence in 14-day intervals for the observed data to the fitted values. (S1 Fig) [34]. Decoding the underlying carriage sequence After fitting the HMM, a Viterbi algorithm with the msm function was used to recursively construct the sequence of pneumococcal carriage with the highest probability through the hidden states [46]. The probability of each hidden state at each observation point, conditionally on all the data was computed using Baum-Welch forward/backward algorithm. Thus, an overall misclassification probability of the observed states given the hidden states was computed. Model estimates of carriage transition intensity and probability were adjusted for misclassification probability (S2 Fig). Sensitivity analysis In a sensitivity analysis, three alternative and potentially more parsimonious models were fitted separately to the data. Fits of these models were compared to the main model using the on Akaike

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

Information Criterion (AIC) [47] and checked whether they yielded qualitatively different results to the main model. Each of the four fitted models assumed the same number of covariates to modify carriage acquisition intensity but varying number of covariates assumed to modify carriage duration. Potential modifiers of carriage duration included age and HIV status for model 1; age, HIV status and antibiotic use for model 2; age, HIV status and viral load based ART status for model 3; and age, HIV status, antibiotic use and viral load based ART status for main model 4 (S1 Table). Further, we examined the impact of alternative stratification of covariates on the changes in carriage transition probabilities: (i) while the main analysis estimated age- and HIV-stratified carriage acquisition rates comparing households with ≥1 HIV-infected adult(s) versus households without HIV-infected adults, in the sensitivity analysis, we estimated age- and HIV-stratified carriage acquisition rates comparing households with 0,1, 2, 3, 4 and 5 HIV-infected adult(s) and (ii) rather than assuming time-homogeneous intensities throughout the study period, we relaxed this assumption by fitting a time-inhomogeneous model with piecewise follow-up periods; 0-99 days, 100-139, 140-199, 200-219 and 220-289 (S3 Fig). Statistical significance was set at <0.05. All analyses were conducted in R v3.5.0 [34,48] and are available via https://github.com/deusthindwa/hmm.pneumococcus.hiv.south-africa. **Ethical approval** The longitudinal pneumococcal carriage data described in this study were obtained from consenting South African children and adults as part of the PHIRST study. The use of data was granted by the University of Witwatersrand, Human Research Ethics Committee (HREC) and the Protocol Review Committee (PRC) under approval #150808, the US CDC's Institutional Review Board relied on the local review (#6840), and the London School of Hygiene & Tropical Medicine Observational Research Ethics Committee under approval #17902.

Results

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

Descriptive analysis A total of 327 households were recruited in the PHIRST study of which 166 (50.8%) had at least one member living with HIV infection. At enrolment, of 1,684 individuals included in the study, 279 (16.6%) were younger children aged less than 5 years old of whom 4 (1.5%) were HIV-infected, and 679 (40.3%) were older children aged between 5-17 years old of whom 31 (4.7%) were HIV-infected. Among the 726 (43.1%) study participants aged 18 years or older ("adults"), 214 (30.4%) were HIVinfected, and 505 (69.6%) were females. Among those HIV-infected adults, 196 (86.7%) self-reported to be on ART, although only 151 (79.5%) had CD4+ cell count of more than 350. Most adults were non-smokers (69.6%) and did not regularly consume alcohol (57.4%). A similar proportion of children lived in households with (50.6%) and without (49.4%) at least one HIV-infected adult. Among 231 younger children with vaccine information available, 227 (98.3%) received first PCV dose at 6 weeks, 225 (97.4%) second dose at 14 weeks and 216 (93.5%) third dose at 9 months of age (Table 1). Carriage prevalence and density Among HIV-uninfected participants, observed pneumococcal carriage prevalence was higher in younger children (range across visits: 56.9-80.5%) than older children (31.7-50.0%) and was lowest in adults (11.5-23.5%) (Fig 2A). Among HIV-infected participants, pneumococcal carriage prevalence fluctuated in younger children (0-100%), in older children (30-77%), and in adults (14-34%) (Fig 2A). The likelihood of detecting pneumococcal carriage during visits was higher for children than adults and for HIV-infected younger children or older children or adults than their HIVuninfected counterparts (Fig 2B). Carriage prevalence among younger HIV-uninfected children was lower in households with less than 6 members (65.5%, 95%CI: 64.5-66.5) than in households with 6-10 (72.5%, 95%CI: 71.5-73.5) or household more than 10 members (85.6%, 95%CI: 82.4-88.8) but it was similar in HIV-infected children across household size groups (Fig 2C). Carriage prevalence fluctuated across visits by HIV-infection and sex in adults, with similar ranges between HIV-

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

uninfected male adults 10.8-25.3% and HIV-uninfected female adults 10.2-24.0%, and between HIVinfected male adults 6.3-40.7% and HIV-infected female adults 12.3-34.6% (S5A Fig). Median pneumococcal carriage density, in genome equivalents per millilitre (GE/ml), was significantly higher in younger children (24,341, 95%CI: 22,638-26,122) than older children (3,490, 95%CI: 3,168-3,754) or adults (476, 95%CI: 429-522). Also, median carriage density was higher in HIV-infected than HIV-uninfected older children (11,156, 95%CI: 8,681-13,948 vs 3,221, 95%CI: 2,911-3,472) or adults (622, 95%CI: 507-714 vs 389, 95%CI: 311-435), and not in younger children (33,050, 95%CI: 22,690-42,293 vs 24,124, 95%CI: 22,547-25,838) (Fig 2D). Conversely, median carriage density was similar between those not on ART compared to those on ART in older children (9,624, 95%CI: 5,289-11,843 vs 8,818, 95%CI: 5,102-12,720) or adults (861, 95%CI: 508-1,001 vs 499, 95%CI: 382-586), and not in younger children (25,430, 95%CI: 13,138-40,245 vs 91,566, 95%CI: 43,355-265,628) (Fig 2E). About 14.4%, 95%CI: 13.7-15.0 of negative NP swab results were estimated probabilistically to be false negatives. Pneumococcal carriage acquisition Overall, pneumococcal carriage acquisition was higher in older children (1.15, 95%CI: 1.08-1.23) and younger children (1.52, 95%CI: 1.38-1.68) than adults. Acquisition of carriage was more frequently observed when at least another household member was infected half a week before (and hence attributed to household transmission) than in previously uninfected households (1.80, 95%CI: 1.68-1.93). Irrespective of age and HIV status, acquisition rates from within the household increased with household size; by 1.05 (95%CI: 1.00-1.10) in households with 6-10 members and by 1.41 (95%CI: 1.24-1.60) in households with 11 or more members compared to households with less than 6 members. However, within household carriage acquisition rates in children, irrespective of age group and HIV status, were not higher in the households with at least one HIV-infected adult (0.95, 95%CI: 0.91-1.01) (Table 2, Fig 3). In addition, daily carriage acquisition rates in HIV-uninfected younger

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

children did not significantly vary between households with HIV-infected female adults (0.14, 95%CI: 0.12-0.17) and those with HIV-infected male adults (0.13, 95%CI: 0.11-0.15) (S5 Fig). We estimated 3.8 carriage acquisition episodes per year, (95%CI: 3.4-4.2) for HIV-infected younger children, 5.9 (95%CI: 5.4-6.3) for HIV-uninfected younger children, 7.4 (95%CI: 6.7-8.1) for HIVinfected older children and 10.6 (95%CI: 10.2-11.0) for HIV-uninfected older children from households with at least one HIV-infected adult, and these were similar to their counterparts from households without HIV-infected adults (3.8, 95%CI: 3.3-4.2 and 5.8, 95%CI: 5.4-6.3, and 7.3, 95%CI: 6.6-8.0 and 10.3, 95%CI: 9.9-10.8, respectively) (Fig 3, S2 Table). Pneumococcal carriage duration The average duration of pneumococcal carriage was highest in HIV-infected and HIV-uninfected younger children (107.9 days, 95%CI: 92.1-124.7 and 56.3 days, 95%CI: 51.1-62.1) followed by HIV-infected and HIV-uninfected older children (33.9 days, 95%CI: 29.9-38.6 and 17.9 days, 95%CI: 16.8-18.5), and HIV-infected and HIV-uninfected adults (11.4 days, 95%CI: 10.2-12.8 and 6.0 days, 95%CI: 5.6-6.3) (Fig 4C, Fig 4D, and S3 Table). Pneumococcal carriage cleared slower in older children (Hazard Ratio [HR]: 0.34, 95%CI: 0.31-0.36) and younger children (HR: 0.10, 95%CI: 0.09-0.12) when compared to adults. Carriage clearance was slower in HIV-infected than in HIV-uninfected individuals (HR: 0.52, 95%CI: 0.46-0.59), and faster in HIV-infected individuals with successfully suppressed viral load than in those without successful viral suppression (HR: 1.29, 95%CI: 1.13-1.47) (Fig 4B, Table 2). Antibiotic use may have accelerated pneumococcal clearance; however, the effect was not statistically significant (HR: 1.47, 95%CI: 0.67-3.25) (Fig 4A, Table 2).

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

Sensitivity analysis In the sensitivity analysis, a model that included age, HIV status, antibiotic use, and ART status as potential modifiers for pneumococcal carriage duration had the lowest AIC score as well as for including both antibiotic use and ART status (S1 Table). Increasing the number of HIV-infected adults within household to 1, 2, 3, 4, and 5 resulted in similar estimates of pneumococcal carriage acquisition in younger or older children (S3A Fig). Our results were also robust when instead of assuming a time homogeneous hidden Markov model, we allowed for the estimation of time varying transition probabilities (S3B Fig) **Discussion** We used a HMM to better understand pneumococcal carriage dynamics, and the role of HIV-infected adults in it, using data from a densely sampled longitudinal South African cohort using data from 115,595 nasopharyngeal swabs. We estimated that children have higher acquisition rates and duration of carriage than adults, and that, within a household, HIV-infected adults are not more likely to transmit pneumococci to children than HIV-uninfected adults. Pneumococcal acquisition events increased with larger household size irrespective of age and HIV status. Although ART use reduced pneumococcal carriage duration in HIV-infected children and adults, they still carry pneumococci for longer than their HIV-uninfected counterparts. Higher household acquisition rates in children than adults have been reported previously [32,49–53], although not consistently across studies [35,54]. This may reflect setting-specific population mixing behaviour and immunisation levels. Similarly, and for the first time in the presence of a mature infant PCV routine vaccination programme, we find that children both have higher acquisition rates than adults and carry pneumococci for longer, making them a likely key source for pneumococcal transmission in and beyond the household [55,56].

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

We postulated that HIV-infected adults were more likely to carry pneumococci and may have higher carriage density which individually or in combination may increase their risk for pneumococcal transmission compared to HIV-uninfected adults. Prior to infant PCV introduction, a study in Malawi showed that HIV-infected adults on ART had higher carriage prevalence than those not on ART [5], and two studies in South Africa also found that HIV-infected adults (mothers) had higher carriage prevalence than their HIV-uninfected counterparts, irrespective of ART status [32,49]. In addition, HIV-infected adults (mothers) were found to transmit pneumococci to their children more often than HIV-uninfected peers [32]. We generated additional evidence showing that, in the PCV era, carriage prevalence is slightly increased in HIV-infected adults on ART compared to HIV-uninfected adults as a result of reduced carriage clearance rates. We also show that median carriage density is higher in HIV-infected than HIV-uninfected adults. However, we find no evidence that carriage density is modified by ART status in HIV-infected adults (Fig 2). Further research may need to investigate whether differential effects of ART on pneumococcal carriage density in adults by country may be driven by types of ART regimens used. Furthermore, our model estimates that the presence of an HIV-infected adult in the household does not increase the risk for pneumococcal carriage acquisition in co-habiting children. Although it is possible that there may have been other HIV-infected adults within households who were not enrolled into the study, it is unlikely this would alter the results given the insensitive acquisition estimates with increasing number of HIV-infected adults within household (S3A Fig). These findings support the notion that ART largely, but not completely, reconstitutes the anti-pneumococcal mucosal immune response in HIV-infected adults [8]. This would imply that HIV-infected adults do not contribute disproportionally to pneumococcal transmission when on ART and hence that their vaccination is unlikely to substantially add to the herd protection already induced by the childhood immunisation programme although vaccination will provide direct protection against IPD in HIV-infected adults. Our observation of increasing pneumococcal carriage acquisition rates with higher household size has also been reported previously [36] and suggests density dependent transmission in the household [57].

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

In line with evidence before infant PCV introduction [32,36], we find that pneumococcal carriage acquisition probabilities from the community were higher in children than in adults irrespective of HIV status, likely in part due to frequent effective contacts among playschool children [49,58] and immature immunity in children relatively to adults. We also estimate that children were twice as likely to get infected from within the household than from the community. However, we base this inference on the identified pneumococcal carriage in a household member at the previous visit. In the absence of serotyping of the pneumococcal isolates, our inferences may be prone to overestimation within household transmission by linking family members who in fact were infected with different pneumococcal serotypes. Similarly, serotyping would enhance our ability to differentiate a single and long carriage episode from almost immediate re-acquisition or the clearance of the dominant serotype while the previously subdominant serotype persists. This may have led to an overestimation of carriage duration and underestimated clearance rates. However, the mean carriage duration of 56 days (51-62) in HIV-uninfected children estimated in this study aligns with studies that used serotype data [32,35,49,59]. While both the estimates for duration of carriage and the contribution of household transmission may be somewhat exaggerated, the lack of serotyping should not have affected our primary outcome, the relative contribution of HIV infected adults to pneumococcal transmission. The use of ART, as inferred from measured viral load in study participants, reduced pneumococcal carriage duration by 22% compared to no ART use within each age group of HIV-infected participants. However, mean pneumococcal carriage duration remained slightly higher than their HIV-uninfected counterparts (Fig 4). Our model also estimated the sensitivity of the swabbing and qPCR testing regime for the detection of pneumococcal carriage. We estimate that about 1 in 7 swabs were misclassified as pneumococcal negative. False negatives might have arisen as a result of the sampling technique or if samples contained insufficient quantities of bacteria to successfully amplify and detect [58]. We assumed 100% specificity of an assay targeting the autolysin gene as the

probability of false positives is seemingly very low [31,59]. Our estimated misclassification probability in this study is within 10-20% range of values that were reported elsewhere [59,60].

In conclusion, we used one of the most densely sampled longitudinal pneumococcal carriage studies to infer the role of HIV-infected adults in pneumococcal transmission in the PCV and ART era. We find that the transmission risk from HIV-infected adults largely aligns with that of their uninfected counterpart. This implies that PCV use in HIV-infected adults who have access to ART would reduce their risk for pneumococcal disease but may have little added benefit over vaccinating other adults to the indirect protection against carriage of the rest of the population.

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

Declaration Funding This research was commissioned by the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal Pathogens under the UK Government. PHIRST study was funded by a cooperative agreement with the United States Centers for Disease Control and Prevention (grant number 1U01IP001048) and the Bill and Melinda Gates Foundation (Grant number: OPP1164778). Acknowledgement DT, OJ are supported by the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal Pathogens (MPRU) using UK aid from the UK Government (16/136/46). AP is supported by the Bill and Melinda Gates Foundation. SF is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). CC and AvG receive grant support through their institution from Sanofi Pasteur. The funders had no involvement in the study design; collection, analysis and interpretation of data; writing of the report; or decision to submit the article for publication. Members of the Prospective Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community Burden and Transmission Dynamics (PHIRST) have played a role of funding-acquisition and administration. The following are members of the PHIRST group: Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa (Amelia Buys, Lorens Maake, Florette Treurnicht, Orienka Hellferscee, Thulisa Mkhencele); Environment and Health Research Unit, South African Medical Research Council, Johannesburg, South Africa (Angie Mathee); Unit for Environmental Science and Management, School of Geo- and Spatial Science, North-West University, Potchefstroom, South Africa (Brigitte Language, Stuart Piketh); School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (Lorens Maake, Floidy Wafawanaka, Ryan G

Wagner, F. Xavier Gómes-Olivé, Kathleen Kahn); Perinatal HIV Research Unit, MRC Soweto

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa (Katlego Mothlaoleng, Limakatso Lebina, Neil A Martinson); Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of America (Neil A Martinson). We are grateful to all individuals who participated in the PHIRST study. We also thank all community leaders from Agincourt Klerksdorp for allowing us to conduct PHIRST study in these areas. **Author contribution** Conceptualization: DT, SF, NF; Methodology: DT, SF, AP; Writing-Original Draft: DT; Writing-Review and Editing: DT, NW, AP, CM, JO, ST, JM, MM, JK, AvG, NF, CC, SF; Funding-Acquisition: DT, CC, AvG. All authors read and approved the final manuscript. **Competing interests** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. **Disclaimer** The findings and conclusions in this publication are those of the authors and do not necessarily represent the official position of the United States Centers for Disease Control and Prevention, the NIHR or the Department of Health and Social Care.

Reference

- 422 1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of 423 disease caused by Streptococcus pneumoniae in children younger than 5 years: global 424 estimates. The Lancet. 2009;374: 893–902. doi:10.1016/S0140-6736(09)61204-6
- 425 2. Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of
 426 Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in
 427 the era of conjugate vaccines: global, regional, and national estimates for 2000–15.
- 428 The Lancet Global Health. 2018;6: e744–e757. doi:10.1016/S2214-109X(18)30247-X
- 3. van Aalst M, Lötsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A, et al.
 Incidence of invasive pneumococcal disease in immunocompromised patients: A
 systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2018;24:
 89–100. doi:10.1016/j.tmaid.2018.05.016
- 433 4. Corcoran M, Vickers I, Mereckiene J, Murchan S, Cotter S, Fitzgerald M, et al. The
 434 epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has
 435 there been a herd effect? Epidemiology & Infection. 2017;145: 2390–2399.
- 436 doi:10.1017/S0950268817001194
- Heinsbroek E, Tafatatha T, Phiri A, Ngwira B, Crampin A, Read J, et al. Persisting high
 prevalence of pneumococcal carriage among HIV-infected adults receiving
 antiretroviral therapy in Malawi. Aids. 2015;29: 1837–1844.
 doi:10.1097/QAD.000000000000055
- Nunes MC, Gottberg A von, Gouveia L de, Cohen C, Kuwanda L, Karstaedt AS, et al.
 Persistent High Burden of Invasive Pneumococcal Disease in South African HIV-Infected
 Adults in the Era of an Antiretroviral Treatment Program. PLOS ONE. 2011;6: e27929.
 doi:10.1371/journal.pone.0027929
- Gill CJ, Mwanakasale V, Fox MP, Chilengi R, Tembo M, Nsofwa M, et al. Impact of
 Human Immunodeficiency Virus Infection on Streptococcus pneumoniae Colonization
 and Seroepidemiology among Zambian Women. J Infect Dis. Oxford Academic;
 2008;197: 1000–1005. doi:10.1086/528806
- Zhang L, Li Z, Wan Z, Kilby A, Kilby JM, Jiang W. Humoral immune responses to
 Streptococcus pneumoniae in the setting of HIV-1 infection. Vaccine. 2015;33: 4430–4436. doi:10.1016/j.vaccine.2015.06.077
- Jochems SP, Weiser JN, Malley R, Ferreira DM. The immunological mechanisms that
 control pneumococcal carriage. PLOS Pathogens. 2017;13: e1006665.
 doi:10.1371/journal.ppat.1006665
- 10. Iwajomo OH, Finn A, Ogunniyi AD, Williams NA, Heyderman RS. Impairment of
 Pneumococcal Antigen Specific Isotype-Switched Igg Memory B-Cell Immunity in HIV
 Infected Malawian Adults. PLOS ONE. 2013;8: e78592.
 doi:10.1371/journal.pone.0078592

459 11. Harries AD, Ford N, Jahn A, Schouten EJ, Libamba E, Chimbwandira F, et al. Act local, 460 think global: how the Malawi experience of scaling up antiretroviral treatment has 461 informed global policy. BMC Public Health. 2016;16: 938. doi:10.1186/s12889-016-462 3620-x 463 12. Jahn A, Harries AD, Schouten EJ, Libamba E, Ford N, Maher D, et al. Scaling-up antiretroviral therapy in Malawi. Bulletin of the World Health Organization. 2016;94: 464 465 772-776. doi:10.2471/BLT.15.166074 466 13. Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, et al. 467 Declining Incidence of Invasive Streptococcus pneumoniae Infections among Persons 468 with AIDS in an Era of Highly Active Antiretroviral Therapy, 1995—2000. J Infect Dis. 469 2005;191: 2038–2045. doi:10.1086/430356 470 14. Everett DB, Mukaka M, Denis B, Gordon SB, Carrol ED, Oosterhout JJ van, et al. Ten 471 Years of Surveillance for Invasive Streptococcus pneumoniae during the Era of 472 Antiretroviral Scale-Up and Cotrimoxazole Prophylaxis in Malawi. PLOS ONE. 2011;6: 473 e17765. doi:10.1371/journal.pone.0017765 474 15. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate 475 vaccine in HIV-infected individuals. Human Vaccines & Immunotherapeutics. 2012;8: 476 161-173. doi:10.4161/hv.18432 477 16. Eley B. Immunization in Patients with HIV Infection. Drugs. 2008;68: 1473–1481. 478 doi:10.2165/00003495-200868110-00001 479 17. De Milito A, Mörch C, Sönnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in 480 HIV-1 infection. AIDS. 2001;15: 957. 481 18. Madhi SA, Kuwanda L, Cutland C, Holm A, Käyhty H, Klugman KP. Quantitative and 482 Qualitative Antibody Response to Pneumococcal Conjugate Vaccine Among African 483 Human Immunodeficiency Virus-Infected and Uninfected Children. The Pediatric 484 Infectious Disease Journal. 2005;24: 410. doi:10.1097/01.inf.0000160942.84169.14 485 19. Swarthout TD, Fronterre C, Lourenço J, Obolski U, Gori A, Bar-Zeev N, et al. High residual 486 carriage of vaccine-serotype Streptococcus pneumoniae after introduction of 487 pneumococcal conjugate vaccine in Malawi. Nature Communications. Nature 488 Publishing Group; 2020;11: 2222. doi:10.1038/s41467-020-15786-9 489 20. Lourenço J, Obolski U, Swarthout TD, Gori A, Bar-Zeev N, Everett D, et al. Determinants 490 of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a 491 modelling study. BMC Medicine. 2019;17. doi:10.1186/s12916-019-1450-2 492 21. Heinsbroek E, Tafatatha T, Phiri A, Swarthout TD, Alaerts M, Crampin AC, et al. 493 Pneumococcal carriage in households in Karonga District, Malawi, before and after 494 introduction of 13-valent pneumococcal conjugate vaccination. Vaccine. 2018;36:

7369-7376. doi:10.1016/j.vaccine.2018.10.021

496 22. Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, et al. Effect of ten-valent 497 pneumococcal conjugate vaccine on invasive pneumococcal disease and 498 nasopharyngeal carriage in Kenya: a longitudinal surveillance study. The Lancet. 2019; 499 doi:10.1016/S0140-6736(18)33005-8 500 23. Sigaúque B, Moiane B, Massora S, Pimenta F, Verani JR, Mucavele H, et al. Early Declines 501 in Vaccine Type Pneumococcal Carriage in Children Less Than 5 Years Old After 502 Introduction of 10-valent Pneumococcal Conjugate Vaccine in Mozambique. The 503 Pediatric Infectious Disease Journal. 2018;37: 1054. 504 doi:10.1097/INF.0000000000002134 505 24. Usuf E, Bottomley C, Bojang E, Cox I, Bojang A, Gladstone R, et al. Persistence of 506 Nasopharyngeal Pneumococcal Vaccine Serotypes and Increase of Nonvaccine 507 Serotypes Among Vaccinated Infants and Their Mothers 5 Years After Introduction of 508 Pneumococcal Conjugate Vaccine 13 in The Gambia. Clin Infect Dis. 2019;68: 1512-509 1521. doi:10.1093/cid/ciy726 510 25. Klugman KP, Rodgers GL. Population versus individual protection by pneumococcal 511 conjugate vaccination. The Lancet. 2019;393: 2102-2104. doi:10.1016/S0140-512 6736(19)30039-X 513 26. Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR, et al. Mapping 514 HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature. 2019;570: 189. 515 doi:10.1038/s41586-019-1200-9 516 27. UNAIDS. Global HIV & AIDS databook [Internet]. Geneva, Switzerland: Joint United 517 Nations Programme on HIV/AIDS; 2017 pp. 1–248. Available: 518 https://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_ 519 en.pdf 520 28. Thindwa D, Pinsent A, Ojal J, Gallagher KE, French N, Flasche S. Vaccine strategies to 521 reduce the burden of pneumococcal disease in HIV-infected adults in Africa. Expert 522 Review of Vaccines. Taylor & Francis; 2020;0: 1-8. doi:10.1080/14760584.2020.1843435 523 524 29. Cohen C, McMorrow M, Martinson NA, Kahn K, Treurnicht FK, Moyes J, et al. Cohort 525 Profile: a Prospective Household cohort study of Influenza, Respiratory Syncytial virus, 526 and other respiratory pathogens community burden and Transmission dynamics in 527 South Africa (PHIRST), 2016-2018. medRxiv. Cold Spring Harbor Laboratory Press; 2021; 528 2021.01.06.21249313. doi:10.1101/2021.01.06.21249313 529 30. Cohen C, Kleynhans J, Moyes J, McMorrow ML, Treurnicht FK, Hellferscee O, et al. 530 Asymptomatic transmission and high community burden of seasonal influenza in an 531 urban and a rural community in South Africa, 2017-18 (PHIRST): a population cohort 532 study. The Lancet Global Health. 2021;9: e863-e874. doi:10.1016/S2214-533 109X(21)00141-8 534 31. Blaschke AJ. Interpreting Assays for the Detection of Streptococcus pneumoniae. Clin 535 Infect Dis. Oxford Academic; 2011;52: S331–S337. doi:10.1093/cid/cir048

536 32. Shiri T, Auranen K, Nunes MC, Adrian PV, van Niekerk N, de Gouveia L, et al. Dynamics of 537 Pneumococcal Transmission in Vaccine-Naïve Children and Their HIV-infected or HIV-538 uninfected Mothers During the First 2 Years of Life. Am J Epidemiol. 2013;178: 1629-1637. doi:10.1093/aje/kwt200 539 540 33. Cox DR, Miller HD. The Theory of Stochastic Processes. CRC Press; 1977. 541 34. Jackson C. Multi-State Models for Panel Data: The msm Package for R. Journal of 542 Statistical Software. 2011;38: 1-28. doi:10.18637/jss.v038.i08 543 35. Lipsitch M, Abdullahi O, D'Amour A, Xie W, Weinberger D, Tchetgen ET, et al. Estimating 544 Rates of Carriage Acquisition and Clearance and Competitive Ability for Pneumococcal 545 Serotypes in Kenya With a Markov Transition Model. Epidemiology. 2012;23: 510–519. 546 doi:10.1097/EDE.0b013e31824f2f32 547 36. Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of 548 pneumococcal carriage in households. Epidemiol Infect. 2004;132: 433–441. 549 37. Melegaro A, Choi Y, Pebody R, Gay N. Pneumococcal Carriage in United Kingdom 550 Families: Estimating Serotype-specific Transmission Parameters from Longitudinal 551 Data. Am J Epidemiol. 2007;166: 228–235. doi:10.1093/aje/kwm076 552 38. Jones E, Epstein D, García-Mochón L. A Procedure for Deriving Formulas to Convert 553 Transition Rates to Probabilities for Multistate Markov Models. Medical Decision 554 Making. 2017;37: 779–789. doi:10.1177/0272989X17696997 555 39. Jackson CH, Sharples LD. Hidden Markov models for the onset and progression of 556 bronchiolitis obliterans syndrome in lung transplant recipients. Statistics in Medicine. 557 2002;21: 113-128. doi:10.1002/sim.886 558 40. Jackson CH, Sharples LD, Thompson SG, Duffy SW, Couto E. Multistate Markov models 559 for disease progression with classification error. Journal of the Royal Statistical Society: 560 Series D (The Statistician). 2003;52: 193–209. doi:10.1111/1467-9884.00351 561 41. Bureau A, Shiboski S, Hughes JP. Applications of continuous time hidden Markov models 562 to the study of misclassified disease outcomes. Statistics in Medicine. 2003;22: 441-563 462. doi:10.1002/sim.1270 564 42. Cooper B, Lipsitch M. The analysis of hospital infection data using hidden Markov 565 models. Biostatistics. 2004;5: 223-237. doi:10.1093/biostatistics/5.2.223 566 43. Satten GA, Longini IM. Markov Chains With Measurement Error: Estimating the 'True' 567 Course of a Marker of the Progression of Human Immunodeficiency Virus Disease. 568 Journal of the Royal Statistical Society Series C (Applied Statistics). 1996;45: 275–309. 569 doi:10.2307/2986089 570 44. McClintock BT, Langrock R, Gimenez O, Cam E, Borchers DL, Glennie R, et al. Uncovering 571 ecological state dynamics with hidden Markov models. Ecology Letters. 2020;23: 1878-572 1903. doi:https://doi.org/10.1111/ele.13610

573 45. Powell MJD. The BOBYQA algorithm for bound constrained optimization without 574 derivatives. Cambridge; 2009. p. 39. Available: 575 http://www.damtp.cam.ac.uk/user/na/NA papers/NA2009 06.pdf 576 46. Viterbi A. Error bounds for convolutional codes and an asymptotically optimum 577 decoding algorithm. IEEE Transactions on Information Theory. 1967;13: 260–269. 578 doi:10.1109/TIT.1967.1054010 579 47. Stone M. An Asymptotic Equivalence of Choice of Model by Cross-Validation and 580 Akaike's Criterion. Journal of the Royal Statistical Society Series B (Methodological). 581 1977;39: 44-47. 582 48. R Core Team (2018). R: A language and environment for statistical computing. R 583 Foundation for Statistical Computing, Vienna, Austria. [Internet]. [cited 28 May 2019]. 584 Available: https://www.r-project.org/ 585 49. Nunes MC, Shiri T, van Niekerk N, Cutland CL, Groome MJ, Koen A, et al. Acquisition of 586 Streptococcus pneumoniae in Pneumococcal Conjugate Vaccine-naïve South African 587 Children and Their Mothers. The Pediatric Infectious Disease Journal. 2013;32: e192. 588 doi:10.1097/INF.0b013e31828683a3 589 50. Heinsbroek E, Tafatatha T, Chisambo C, Phiri A, Mwiba O, Ngwira B, et al. Pneumococcal 590 Acquisition Among Infants Exposed to HIV in Rural Malawi: A Longitudinal Household 591 Study. Am J Epidemiol. 2016;183: 70–78. doi:10.1093/aje/kwv134 592 51. Turner P, Turner C, Jankhot A, Helen N, Lee SJ, Day NP, et al. A Longitudinal Study of 593 Streptococcus pneumoniae Carriage in a Cohort of Infants and Their Mothers on the 594 Thailand-Myanmar Border. PLOS ONE. Public Library of Science; 2012;7: e38271. 595 doi:10.1371/journal.pone.0038271 596 52. Hussain M, Melegaro A, Pebody RG, George R, Edmunds WJ, Talukdar R, et al. A 597 longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in 598 a UK setting. Epidemiology & Infection. 2005;133: 891–898. 599 doi:10.1017/S0950268805004012 600 53. Althouse BM, Hammitt LL, Grant L, Wagner BG, Reid R, Larzelere-Hinton F, et al. 601 Identifying transmission routes of Streptococcus pneumoniae and sources of 602 acquisitions in high transmission communities. Epidemiology and Infection. 2017;145: 603 2750-2758. doi:10.1017/S095026881700125X 604 54. Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, Wanjiru E, et al. Rates of Acquisition 605 and Clearance of Pneumococcal Serotypes in the Nasopharynges of Children in Kilifi 606 District, Kenya. J Infect Dis. 2012;206: 1020–1029. doi:10.1093/infdis/jis447 607 55. Flasche S, Lipsitch M, Ojal J, Pinsent A. Estimating the contribution of different age 608 strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a 609 modelling study. BMC Medicine. 2020;18. doi:10.1186/s12916-020-01601-1

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626627

628

629

630

56. Wyllie AL, Warren JL, Regev-Yochay G, Givon-Lavi N, Dagan R, Weinberger DM. Serotype Patterns of Pneumococcal Disease in Adults Are Correlated With Carriage Patterns in Older Children. Clinical Infectious Diseases. 2020; doi:10.1093/cid/ciaa1480 57. Endo A, Uchida M, Kucharski AJ, Funk S. Fine-scale family structure shapes influenza transmission risk in households: Insights from primary schools in Matsumoto city, 2014/15. PLOS Computational Biology. Public Library of Science; 2019;15: e1007589. doi:10.1371/journal.pcbi.1007589 58. Weinberger DM, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children. Am J Epidemiol. 2019;188: 160–168. doi:10.1093/aje/kwy219 59. Lees JA, Croucher NJ, Goldblatt D, Nosten F, Parkhill J, Turner C, et al. Genome-wide identification of lineage and locus specific variation associated with pneumococcal carriage duration. In: eLife [Internet]. 25 Jul 2017 [cited 24 Jun 2019]. doi:10.7554/eLife.26255 60. Abdullahi O, Wanjiru E, Musyimi R, Glass N, Scott JAG. Validation of Nasopharyngeal Sampling and Culture Techniques for Detection of Streptococcus pneumoniae in Children in Kenya. Journal of Clinical Microbiology. American Society for Microbiology Journals; 2007;45: 3408-3410. doi:10.1128/JCM.01393-07

Table 1. Baseline demographic and clinical characteristics of children and adults who were followed up twice weekly for ten months for nasopharynx swabbing for pneumococcal carriage in South African households between 2016 and 2018.

	Total	Younger children	Older children	Adults
Description		<5 years	5-17 years	≥18 years
•	N=1,684	n=279 (16.6%)	n=679 (40.3%)	n=726 (43.1%)
Mean age (SD)	22.1 (±19.8)	2.2 (±1.3)	10.5 (±3.7)	40.5 (±16.7)
Study site				
Agincourt (rural)	849 (50.4)	171 (61.3)	376 (55.4)	302 (41.6)
Klerksdorp (semi-urban)	835 (49.6)	108 (38.7)	303 (44.6)	424 (58.4)
Sex				, , ,
Female	1,009 (59.9)	137 (49.1)	367 (54.1)	505 (69.6)
Male	675 (40.1)	142 (50.9)	312 (45.9)	221 (30.4)
HIV status				
Negative (-)	1,379 (84.7)	256 (98.5)	634 (95.3)	489 (69.6)
Positive (+)	249 (15.3)	4 (1.5)	31 (4.7)	214 (30.4)
Viral-load based ART status [†]				
Not on ART	93 (40.8)	1 (50.0)	13 (52.0)	79 (39.3)
On ART	135 (59.2)	1 (50.0)	12 (48.0)	122 (60.7)
Self-reported ART status				
Not on ART	30 (13.2)	0(0.0)	1 (3.8)	29 (14.5)
On ART	198 (86.8)	2 (100.0)	25 (96.2)	171 (85.5)
Mean CD4 count (SD)	673 (±430)	1,210 (±13.4)	857 (±418)	645 (±426)
CD4+ cell count [‡]				
Low	49 (22.8)	0(0.0)	10 (43.5)	39 (20.5)
High	166 (77.2)	2 (100.0)	13 (56.5)	151 (79.5)
Living with ≥1 HIV+ adults				
No	818 (48.7)	133 (47.8)	346 (51.1)	339 (46.9)
Yes	860 (51.3)	145 (52.2)	331 (48.9)	384 (53.1)
PCV13 doses received [#]				
At 6 weeks	227 (98.3)	227 (98.3)	N/A	N/A
At 14 weeks	225 (97.4)	225 (97.4)	N/A	N/A
At 9 months	216 (93.5)	216 (93.5)	N/A	N/A
Smoking (≥18 years)				
No	505 (69.6)	N/A	N/A	505 (69.6)
Yes	221 (30.4)	N/A	N/A	221 (30.4)
Alcohol use (≥18 years)				
No	417 (57.4)	N/A	N/A	417 (57.4)
Yes	309 (42.6)	N/A	N/A	309 (42.6)

[†] ART use status based on viral load results (on ART = Undetected; Not on ART = <20 copies per ml)

[‡] Low CD4+ count ≤350 cells/mm³ and high CD4+ count >350 cells/mm³ in adults, and low CD4+ count

^{≤750} cells/mm³ and high CD4+ count >750 cells/mm³ in children, in HIV-INFECTED only

[#] Pneumococcal conjugate vaccine (PCV13) vaccination status in younger children from available records Standard deviation (SD)

N/A not applicable

Table 2. Effects of included covariates on pneumococcal acquisition and clearance rates estimated in the hidden Markov model.

Description	Hazard Ratio (95%CI) [‡]
Pneumococcal carriage acquisition	
Age in years (y)	
Adult, ≥18y	Reference
Older child, 5-17y	1.15 (1.08-1.23)
Younger child, <5y	1.52 (1.38-1.68)
HIV status	
Negative	Reference
Positive	0.95 (0.87- 1.04)
Children living with ≥1 HIV-infected adults	
No	Reference
Yes	0.95 (0.91- 1.01)
Place of carriage exposure	
Community	Reference
Within household	1.80 (1.68- 1.93)
Household size	
<6 members	Reference
6-10 members	1.05 (1.00-1.10)
11+ members	1.41 (1.24-1.60)
Pneumococcal carriage clearance	
Age in years (y)	
Adult, ≥18y	Reference
Older child, 5-17	0.34 (0.31-0.36)
Younger child, <5y	0.10 (0.09-0.12)
HIV status	
Negative	Reference
Positive	0.52 (0.46-0.59)
Antibiotic use	
No	Reference
Yes	1.47 (0.67-3.25)
Viral load-based ART status [†]	
Not on ART	Reference
On ART	1.29 (1.13-1.47)
† ART use status based on viral load results ‡ 95% confidence interval (95%CI)	




Figure 1. Susceptible-infected-susceptible (SIS) hidden Markov model schemas of pneumococcal carriage dynamics in South African households between 2016-2018. Continuous-time time-homogeneous hidden Markov model where X(t) represents hidden states, and Y(t) observed states, and in which Y(t) is conditionally independent given X(t) and the Markov property holds (A). Pneumococcal nasopharynx (NP) carriage sequence of a specified individual representing hidden and observed states, with a probability that an individual truly carrying a pneumococcal serotype may be detected negative by a real-time quantitative polymerase chain reaction test (B). An SIS hidden Markov model structure that captures a snapshot of part A and carriage sequence of part B in order to estimate transition rates and probability of misclassification/false negative (C). Transition intensity matrix, Q, and emission matrix, E, respectively capture the SIS model transition rates and emission or misclassification probability in part C to compute the maximum likelihood estimates of transition intensities and misclassification probability (D).




Figure 2. Human immunodeficiency virus (HIV)-stratified pneumococcal carriage dynamics in younger children (<5 years-old), older children (5-17 years-old) and adults (≥18 years-old) in South African households between 2016-2018. Age and HIV-stratified pneumococcal carriage prevalence by different nasopharyngeal sampling visits (A), the likelihood of detecting pneumococcal carriage during visits (B), pneumococcal carriage prevalence by household sizes with 95% confidence intervals (CI) (C) and carriage densities with mean (black diamond), median and associated 95%CI of median, 25th and 75th percentiles, minimum and maximum, and outlier where carriage density is measured as genome equivalents per millilitre (GE/ml) (D). Age and antiretroviral therapy (ART) stratified carriage density with mean (red diamonds), median and associated 95%CI of median, 25th and 75th percentiles, minimum and maximum, and outlier (notched boxplot) (E)




Figure 3. Community and within household (HH) acquisitions of pneumococcal carriage in younger children (<5 years-old), older children (5-17 years-old) and adults (≥18 years-old) in South African households between 2016-2018. Age and human immunodeficiency virus (HIV) stratified estimates of community carriage acquisition probability per day (A) and within household carriage acquisition probability per day over the total follow-up period (B), comparing household without HIV-infected adult(s) (HIV-) to households with HIV-infected adult(s) (+).




Figure 4. Duration of pneumococcal carriage in younger children (<5 years-old), older children (5-17 years-old) and adults (≥18 years-old) in South African households between 2016-2018. Age and human immunodeficiency virus (HIV) stratified average carriage duration in days comparing individuals on antibiotics (ABX) (triangular shape) to those not on ABX (circular shape) (A), and individuals on antiretroviral therapy (ART) (triangle shape) to those not on ART (circle shape) (B). Age and HIV stratified overall average carriage duration in days (C). Age and HIV stratified daily probability of carriage clearance (D).